| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
VANCOUVER, May 19, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN, OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced the filing of a key Patent Cooperation Treaty ("PCT") patent application directed to the Company's biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids.
The PCT patent application entitled "Compositions and Methods for Biosynthesis of Terpenoids or Cannabinoids in a Heterologous System" was initially filed as two separate United States Provisional Patent applications and further addresses the enablement and maximization of cannabinoid production through optimization of the precursor substrates needed to support specific cannabinoid synthesis.
"This PCT filing is on schedule following our previously filed provisional patent application submissions last year," stated Eric Hsu, PhD, InMed's Senior Vice President, Preclinical Research and Development. Dr. Hsu added, "We continue to pursue our strategy of aggressively protecting our ongoing developments in our pharmaceutical grade cannabinoid manufacturing program."
The PCT is an international patent law treaty, which provides a unified procedure for filing patent applications to protect inventions in each of its member states. There are 151 member countries within the PCT, enabling near-global patent coverage through successful patent prosecution in the U.S., Japan, Europe, Canada, Australia, New Zealand, China, Brazil, Russia, India, as well as many others.
